Respecting upper facial anatomy for treating the glabella with neuromodulators to avoid medial brow ptosis-A refined 3-point injection technique.

Autor: Cotofana S; Department of Clinical Anatomy, Mayo Clinic College of Medicine and Science, Rochester, MN, USA., Pedraza AP; Private Practice, Bogota, Colombia., Kaufman J; Skin Associates of South Florida and Skin Research Institute, Coral Gables, FL, USA., Avelar LET; Private Practice, Belo Horizonte, Brazil., Gavril DL; Private Practice, Cluj-Napoca, Romania., Hernandez CA; CH Dermatologia, Medellin, Colombia., Onishi EC; Private Practice, Manila, Philippines., Nikolis A; Clinical Research Unit, Erevna Innovations Inc, Montreal, Quebec, Canada.; Division of Plastic Surgery, McGill University, Montreal, Quebec, Canada., Sakuma T; Private Practice, Campo Grande, Brazil., Frank K; Department for Hand, Plastic and Aesthetic Surgery, Ludwig-Maximilian University Munich, Munich, Germany.
Jazyk: angličtina
Zdroj: Journal of cosmetic dermatology [J Cosmet Dermatol] 2021 Jun; Vol. 20 (6), pp. 1625-1633. Date of Electronic Publication: 2021 Apr 16.
DOI: 10.1111/jocd.14133
Abstrakt: Background: Current injection algorithms for treating the glabella rely on a five- or seven-point injection technique with possible medial eyebrow ptosis and lateral eyebrow elevation as undesirable outcomes.
Objective: The objective of this study was to investigate the efficacy and safety profile of a refined 3-point injection technique targeting horizontal and vertical glabellar lines.
Methods: A total of n=105 patients (27 males and 78 females) with a mean age of 40.90 ± 9.2 years were investigated. The injection technique relied on targeting the muscular origin of the procerus and the corrugator supercilii muscles exclusively. The time of effect onset and the injection-related outcome 120 days after the treatment was evaluated using the 5-point glabellar line severity scale.
Results: The onset of the neuromodulator effect was on average 3.5 ± 1.5 days. There was no statistically significant difference in the amplitude of movement before or 14 days after the treatment with 2.99 ± 4.4 mm vs. 3.39 ± 3.6 mm (p = 0.149) for the medial head of the eyebrow and with 3.18 ± 4.7 mm vs. 3.33 ± 4.3 mm (p = 0.510) for the lateral head of the eyebrow, respectively.
Conclusion: Incorporating anatomic concepts into clinical practice for glabellar frown line neuromodulator treatments with the investigated 3-point injection technique resulted in the absence of adverse events like eyebrow ptosis, upper eyelid ptosis, medial eyebrow ptosis, and lateral frontalis hyperactivity. This technique demonstrated efficacy throughout the 4-month study period.
(© 2021 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: